Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma

Pancreas

Volumn 12, Issue 1, 1996, Pages 10-17

  Rall, Christopher J N ^a   Yan, Yu Xin ^a   Graeme Cook, Fiona ^a   Beauchamp, Roberta ^a   Yandell, David W ^b   Povoski, Stephen P ^c   Rustgi, Anil K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Ki ras; p53; Pancreatic ductal adenocarcinoma; Point mutations

Indexed keywords

GROWTH FACTOR; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; GENE ACTIVATION; HUMAN; HUMAN TISSUE; METASTASIS; ONCOGENE RAS; PANCREAS ADENOCARCINOMA; POINT MUTATION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0030063636     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199601000-00002     Document Type: Article

References (46)

1. Fernandez-del Castillo C, Warshaw AL. Diagnosis and preoperative evaluation of pancreatic cancer, with implications for management. Gastroenterol Clin North Am 1990; 19:915-33.
2. Bueno de Mesquita HB, Maisonneuve PCJM, Runia S, Boyle P. Life-time history of smoking and exocrine carcinoma of the pancreas: a population-based case control study in The Netherlands. Int J Cancer 1991;49:816-22.
3. Ghadirian P, Simard A, Baillargeon J. Tobacco, alcohol, and coffee and cancer of the pancreas. Cancer 1991;67: 2664-70.
4. Farrow DC, Davis S. Risk of pancreatic cancer in relation to medical history and the use of tobacco, alcohol and coffee. Int J Cancer 1990;45:816-20.
5. Ekbom A, Mclaughlin JK, Karlsson B, et al. Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Inst 1994;86:625-7.
6. Yanagisawa A, Ohtake K, Ohashi K, et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993;53:953-6.
7. Bollag G, McCormick F. Regulators and effectors of ras proteins. Annu Rev Cell Biol 1991;7:601-32.
8. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
9. Hruban RH, van Mansfeld ADM, Offerhaus GJA, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. Am J Pathol 1993;143:545-54.
10. Motojima K, Urano T, Nagata Y, Shiku H, Tsunoda T, Kanematsu T. Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Am J Gastroenterol 1991;86:1784-8.
11. Grunewald K, Lyons J, Frohlich A, et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037-41.
12. Smit VTHBM, Boot AJM, Smits AMM, Gleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic carcinomas. Nucleic Acids Res 1988;16:7773-82.
13. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;48:4682-9.
14. Aoki Y, Lee JC, Pillai S, Isselbacher KJ, Rustgi AK. Radiolabeled polymerase chain reaction assay for detection of ras oncogene point mutations in tumors. Clin Chem 1994; 40:705-9.
15. Lin S-Y, Chen P-H, Wang C-K, et al. Mutation analysis of K-ras oncogenes in gastroenterologic cancers by amplified created restriction sites method. Am J Clin Pathol 1993; 100:686-9.
16. Urban T, Ricci S, Grange J-D, et al. Detection of c-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst 1993;85:2008-12.
17. Kumar R, Barbarcid M. Oncogene detection at the single cell level. Oncogene 1988;3:647-51.
18. Greenblatt MS, Bennett WP, Hollenstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78.
19. Hollenstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;49:53.
20. Ruggeri B, Zhang S-Y, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJP. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor suppressor genes. Oncogene 1992;7:1503-11.
21. Orita M, Iwahawa H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989;86:2766-70.
22. Toguchida J, Yamagucchi T, Ritchie B, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcoma. Cancer Res 1992;52:6194-9.
23. Yandell DW, Dryja TP. Detection of DNA sequence polymorphisms by enzymatic amplification and direct genomic sequencing. Am J Hum Genet 1989;45:547-55.
24. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutation and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993;90:4961-5.
25. Thor AD, Moore II DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
26. Quaife CJ, Pinkert CA, Ornitz DM, Palmiter RD, Bnnster RL. Pancreatic neoplasia induced by ras expression in acinar cells on transgenic mice. Cell 1987;48:1023-34.
27. Hoorens A, Lemoine NR, McLellan E, et al. Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol 1993; 143:685-98.
28. Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994;54:1556-60.
29. Yashiro T, Fulton N, Hara H, et al. Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery 1993;114:758-64.
30. Tabata T, Fujimori T, Maeda S, Yamamoto M, Saitoh Y. The role of ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis. Intl J Pancreatol 1993;14: 237-44.
31. Lemoine NR, Jain S, Hughes CM, et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992;102:230-6.
32. a. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73.
33. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-82.
34. Kalthoff H, Schmiegel W, Roeder C, et al. p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 1993;8:289-98.
35. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33.
36. Mahewaren S, Park S, Bernard A, et al. Physical and functional interactions between WT1 and p53 proteins. Proc Natl Acad Sci USA 1993;96:5100-4.
37. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992;356:215-21.
38. Taylor WR, Eagan SE, Mowat M, Greenberg AH, Wright JA. Evidence for synergistic interactions between ras, myc and a mutant form of p53 in cellular transformation and tumor dissemination. Oncogene 1992;7:1383-90.
39. Hicks GG, Egan SE, Greenberg AH, Mowat M. Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest. Mol Cell Biol 1991;11:1344-52.
40. Zambetti GP, Olson D, Labrow M, Levine AJ. A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs. Proc Natl Acad Sci USA 1992;89:3952-6.
41. Garbisa S, Pozzatti R, Muschel RJ, et al. Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a. Cancer Res 1987;47:1523-8.
42. Kerr LD, Holt JT, Matrisian LM. Growth factors regulate transin gene expression by c-fos-dependent and c-fos independent pathways. Science 1988;242:1424-7.
43. Denhardt DT, Greenberg AH, Egan SE, Hamilton RT, Wright JA. Cysteine protinase cathepsin L expression correlates closely with the metastatic potential of H-ras transformed murine fibroblasts. Oncogene 1987;2:55-9.
44. Hofmann M, Rudy W, Gunthert U, et al. A link between ras and metastatic behavior of tumor cells: ras induces CD44 promotor activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res 1993;53:1516-21.
45. Jawal HH, Cano-Gauci DF, Buick RN, Filmus J. Activated ras and src induce CD44 overexpression in rat intestinal epithelial cells. Oncogene 1994;9:417-23.
46. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.